Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology; TRUTH Study (Kanagawa PTCA Conference Regression Study 5; KPCR5)

Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology; TRUTH Study (Kanagawa PTCA Conference Regression Study 5; KPCR5) - Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology; TRUTH Study (Kanagawa PTCA Conference Regression Study 5; KPCR5)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000311

Enrollment

160

Registered

2006-01-25

Start date

2005-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with stable or unstable angina

Interventions

pitavastain group pravastatin group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stable or unstable angina received PCI whose LDL-cholesterollevel is above 140mg/dL

Exclusion criteria

Exclusion criteria: 1)Patients currently medicated with statins or other lipid lowering therapy 2)Patients meeting the contraindications or relative contraindications for pitavastatin and pravastatin 3)Patients with hepatic disorder (AST or ALT greater than 2.5 times of the normal upper limits) 4)Patients with renal dysfunction (serum creatinine 2.0mg/dL or higher) 5)Patients with a history of severe muscular disorder or increased CK (CPK) greater than 2.5 times of the normal upper limit 6)Patients with acute myocardial infarction occurred within 24 hours 7)Patients failed to PCI 8)Patients with cerebrovascular accident occurred within 1 month 9)Patients with concurrent or a history of malignant disease within 5 years 10)Patients receiving LDL apheresis 11)Patients with homozygous familial hypercholesterolemia 12)Patients requiring the following prohibited concomitant drugs 13)Drug abusers 14)Patients participating in other studies 15)Patients ineligible for the study determined by physicians

Design outcomes

Primary

Measure	Time frame
Change of tissue characteristics in coronary plaque evaluated by intravascular ultrasound (IVUS) with Virtual Histology	—

Countries

Japan

Contacts

Public ContactTsuyoshi Nozue

Yokohama Sakae Kyosai Hospital Department of Internal medicine, Division of Cardiology

yk411015@fsinet.or.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026